NCT01408030 - North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | Biotech Hunter

Enrollment

123

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Telangiectasia, Hereditary HemorrhagicEpistaxis

Interventions

DRUG

Sterile saline

0.9%, 0.1 ml spray in each nostril bid

DRUG

Bevacizumab

1% solution in saline, 0.1 ml spray in each nostril bid

DRUG

Estriol

0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid

DRUG

Tranexamic Acid

10% solution in saline, 0.1 ml spray in each nostril bid

Trial Locations (6)

Johns Hopkins University, Baltimore

Georgia Regents University, Augusta

Washington University School of Medicine, St Louis

University of Utah, Salt Lake City

University of California Los Angeles, Los Angeles

Oregon Health Sciences University, Portland